Transaction in Own Shares


Novo Nordisk A/S - Share repurchase programme

On 29 January 2009 Novo Nordisk initiated its share repurchase
programme in accordance with the provisions of the European
Commission's regulation no 2273/2003 of 22 December 2003, also
referred to as the Safe Harbour rules.

Under the programme Novo Nordisk will repurchase B shares for an
amount up to DKK 3.0 billion in the period from 29 January 2009 to 5
August 2009.

Since the announcement as of 2 March 2009, the following transactions
have been made under the programme:


                      Number of       Average          Transaction
                       shares       purchase           value,
                                     price                DKK
Accumulated, last
announcement          1,660,000                           504,426,150
2 March 2009             75,000           280.12           21,009,000
3 March 2009             80,000           273.59           21,887,120
4 March 2009             75,000           273.64           20,523,000
5 March 2009             75,000           274.70           20,602,500
6 March 2009             75,000           260.92           19,569,000
Accumulated under the
programme             2,040,000                           608,016,770


Transactions related to Novo Nordisk's incentive programmes have
resulted in an increase of 48,117 B-shares in Novo Nordisk's holding
of treasury shares. The shares in these transactions were not part of
the Safe Harbour repurchase programme.

With the transactions stated above, Novo Nordisk owns a total of
26,892,552 treasury shares, corresponding to 4.2% of the share
capital. The total amount of shares in the company is 634,000,000
including treasury shares.

Novo Nordisk is a healthcare company and a world leader in diabetes
care. In addition, Novo Nordisk has a leading position within areas
such as haemostasis management, growth hormone therapy and hormone
replacement therapy. Novo Nordisk manufactures and markets
pharmaceutical products and services that make a significant
difference to patients, the medical profession and society. With
headquarters in Denmark, Novo Nordisk employs more than 27,000
employees in 81 countries, and markets its products in 179 countries.
Novo Nordisk's B shares are listed on the stock exchanges in
Copenhagen and London. Its ADRs are listed on the New York Stock
Exchange under the symbol 'NVO'. For more information, visit
novonordisk.com.

Further information:


Media:                 Investors:

Outside North America: Outside North America:
Mette Kruse Danielsen  Mads Veggerby Lausten
Tel: (+45) 4442 3883   Tel: (+45) 4443 7919
mkd@novonordisk.com    mlau@novonordisk.com

                       Kasper Roseeuw Poulsen
                       Tel: 4442 4471
                       krop@novonordisk.com

In North America:      In North America:
Sean Clements          Hans Rommer
Tel: (+1) 609 514 8316 Tel: (+1) 609 919 7937
secl@novonordisk.com   hrmm@novonordisk.com


Company Announcement no 13 / 2009

Attachments

Company Announcement no 13  2009.pdf